Skip to main content

Table 3 Characteristics of patients with worsening pre-existing PNS after immunotherapy (cohort 1) or newly diagnosed PNS following immunotherapy (cohort 2)

From: Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Outcome of patients with worsening or newly diagnosed PNS

Cohort 1 (pre-existing PNS)

n = 8 patients with PNS worsening

Cohort 2 (newly diagnosed PNS)

n = 16 patients

Total

n = 24 patients

Time from initiation of immunotherapy to PNS worsening (cohort 1) or new diagnosis of a PNS (cohort 2), median (range), in months

0.9 (0.5–2.8)

1.6 (0.5–6.4)

1.4 (0.5–6.4)

Antitumor response at time of worsening or newly diagnosed PNS, n (%)

 - CR

2 (25)

1 (6)

3 (13)

 - PR

2 (25)

5 (31)

7 (30)

 - SD

2 (25)

10 (63)

12 (50)

 - PD

2 (25)

0

2 (8)

Best overall antitumor response

 - CR

2 (25)

1 (6)

3 (13)

 - PR

3 (38)

5 (31)

8 (33)

 - SD

1 (13)

8 (50)

9 (38)

 - PD

2 (25)

2 (13)

4 (17)

Impact of PNS on immunotherapy, n (%)

 - temporary discontinuation

2 (25)

4 (25)

6 (25)

 - permanent discontinuation

5 (62)

9 (56)

14 (58)

 - no discontinuation

1 (13)

3 (19)

4 (17)

  1. CR Complete response, CTCAE Common Terminology Criteria for Adverse Events, PD Progressive disease, PNS Paraneoplastic syndrome, PR Partial response, SD Stable disease